The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Daratumumab vs isatuximab in the treatment of multiple myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, compares and contrasts the use of daratumumab and isatuximab in the treatment of multiple myeloma. Dr Usmani explains that whilst the efficacy of these agents is similar, they have different dosing schedules and routes of administration. In addition, data has shown that these two agents should not be used one after the other. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
